Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

January 31, 2006

Study Completion Date

April 30, 2007

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

CS-917

DRUG

metformin hydrochloride

DRUG

pioglitazone

Trial Locations (66)

15009

Beaver

15206

Pittsburgh

19020

Bensalem

19696

Reading

19805

Wilmington

20745

Oxon Hill

27103

Winston-Salem

27612

Raleigh

28262

Charlotte

28645

Lenoir

29621

Anderson

31093

Warner Robins

32308

Tallahassee

33028

Pembroke Pines

33156

Miami

33308

Fort Lauderdale

33401

West Palm Beach

33709

St. Petersburg

34613

Brooksville

34741

Kissimmee

35205

Birmingham

35476

Northport

39150

Port Gibson

39159

Rolling Fork

43015

Delaware

43302

Marion

45219

Cincinnati

48152

Livonia

48235

Detroit

49601

Cadillac

49643

Interlochen

53719

Madison

64024

Excelsior Springs

66216

Shawnee Mission

66614

Topeka

71913

Hot Springs

73103

Oklahoma City

77024

Houston

77566

Lake Jackson

78229

San Antonio

78404

Corpus Christi

85014

Phoenix

85201

Mesa

85282

Tempe

89052

Henderson

89103

Las Vegas

90201

Cudahy

90806

Long Beach

91307

West Hills

91604

Studio City

91978

Spring Valley

92083

Vista

94598

Walnut Creek

95661

Roseville

95841

Sacramento

98502

Olympia

Unknown

Sebastian

Rome

Topeka

Charleston

Greer

Nashville

North Richland Hills

Burke

07202

Elizabeth

08755

Toms River

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT00290940 - Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917 | Biotech Hunter | Biotech Hunter